SG11201910183SA - C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof - Google Patents

C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof

Info

Publication number
SG11201910183SA
SG11201910183SA SG11201910183SA SG11201910183SA SG 11201910183S A SG11201910183S A SG 11201910183SA SG 11201910183S A SG11201910183S A SG 11201910183SA SG 11201910183S A SG11201910183S A SG 11201910183SA
Authority
SG
Singapore
Prior art keywords
helsingin
yliopisto
fragment
sequence
international
Prior art date
Application number
Other languages
English (en)
Inventor
Mart Saarma
Mikko Airavaara
Merja Voutilainen
Li Ying Yu
Maria Lindahl
Original Assignee
Helsingin Yliopisto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsingin Yliopisto filed Critical Helsingin Yliopisto
Publication of SG11201910183SA publication Critical patent/SG11201910183SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SG11201910183S 2017-05-04 2018-05-04 C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof SG11201910183SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20175392 2017-05-04
PCT/FI2018/050332 WO2018202957A1 (en) 2017-05-04 2018-05-04 C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof

Publications (1)

Publication Number Publication Date
SG11201910183SA true SG11201910183SA (en) 2019-11-28

Family

ID=62218004

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201910183S SG11201910183SA (en) 2017-05-04 2018-05-04 C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof

Country Status (12)

Country Link
US (1) US20200071372A1 (ja)
EP (1) EP3619227A1 (ja)
JP (1) JP7384672B2 (ja)
KR (1) KR20200003889A (ja)
CN (1) CN110831960A (ja)
AU (1) AU2018263087B2 (ja)
BR (1) BR112019023116A2 (ja)
CA (1) CA3062241A1 (ja)
MX (1) MX2019013157A (ja)
RU (1) RU2019136495A (ja)
SG (1) SG11201910183SA (ja)
WO (1) WO2018202957A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021519578A (ja) * 2018-03-29 2021-08-12 ヘルシンギン ユリオピストＨｅｌｓｉｎｇｉｎ Ｙｌｉｏｐｉｓｔｏ Ｃ末端ｃｄｎｆ断片、それらを含む医薬組成物、並びにそれらの使用
EP3838912A1 (en) 2019-12-20 2021-06-23 Herantis Pharma Oyj Retro-inverso peptides
EP3838345A1 (en) 2019-12-20 2021-06-23 Herantis Pharma Oyj Macrocyclic peptides
WO2021160938A1 (en) 2020-02-13 2021-08-19 Herantis Pharma Oyj Systemic administration of a pharmaceutical composition comprising cdnf or manf polypeptide for use in the treatment of reperfusion injury
CN117018231B (zh) * 2023-08-16 2024-05-10 科辉智药(深圳)新药研究中心有限公司 用于治疗神经病变的基因疗法及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
WO2002079246A2 (en) * 2001-03-30 2002-10-10 Geneprot, Inc. Human arginine-rich protein-related compositions
CA2633468C (en) 2005-12-14 2014-02-18 Licentia Ltd Novel neurotrophic factor protein and uses thereof
FI20080326A0 (fi) * 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
FI20115870A0 (fi) * 2011-09-05 2011-09-05 Urmas Arumaee Neuroprotektiiviset soluihin tunkeutuvat peptidit
WO2014191630A2 (en) 2013-05-28 2014-12-04 Helsingin Yliopisto Non-human animal model encoding a non-functional manf gene
WO2015149005A1 (en) * 2014-03-28 2015-10-01 Buck Institute For Research On Aging Methods and compositions for modulating the immune system
WO2016057579A1 (en) 2014-10-06 2016-04-14 Amarantus Bioscience Holdings, Inc. Methods and compositions for treating retinal disorders

Also Published As

Publication number Publication date
WO2018202957A1 (en) 2018-11-08
CA3062241A1 (en) 2018-11-08
BR112019023116A2 (pt) 2020-07-28
JP2020518261A (ja) 2020-06-25
RU2019136495A (ru) 2021-06-04
AU2018263087B2 (en) 2021-12-16
AU2018263087A1 (en) 2019-11-28
EP3619227A1 (en) 2020-03-11
US20200071372A1 (en) 2020-03-05
JP7384672B2 (ja) 2023-11-21
KR20200003889A (ko) 2020-01-10
CN110831960A (zh) 2020-02-21
MX2019013157A (es) 2020-08-03

Similar Documents

Publication Publication Date Title
SG11201910183SA (en) C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201811432WA (en) Rna for cancer therapy
SG11201810162PA (en) Polynucleotides encoding citrin for the treatment of citrullinemia type 2
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201909303TA (en) Point of delivery cold slurry generation
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201805001UA (en) Method of treating influenza a
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11202000494UA (en) Drug delivery composition
SG11201804440XA (en) Chemical reprogramming of human glial cells into neurons with small molecule cocktail